IRLAB Therapeutics AB financials
IRLAB Therapeutics AB
549300JAT34LHEI0DH60 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | SEK 94.6M | SEK 5.7M |
| Other income | SEK 19.5M | SEK 42.0K |
| Operating expenses | SEK 189.2M | SEK 186.5M |
| Employee benefits expense | SEK 46.2M | SEK 53.1M |
| Operating profit (EBIT) | -SEK 75.1M | -SEK 180.8M |
| Net finance income / (cost) | -SEK 8.0M | SEK 2.9M |
| Finance costs | SEK 10.5M | SEK 199.0K |
| Profit before tax | -SEK 83.1M | -SEK 177.8M |
| Income tax expense | SEK 0 | SEK 0 |
| Profit for the year | -SEK 83.1M | -SEK 177.8M |
| Total comprehensive income | -SEK 83.1M | -SEK 177.8M |
| Per share | ||
| Basic EPS | SEK -1.60 | SEK -3.43 |
| Diluted EPS | SEK -1.60 | SEK -3.43 |
| Free cash flow / share | SEK -1.27 | SEK -3.18 |
| Cash flow statement | ||
| Net cash from operating activities | -SEK 65.6M | -SEK 164.8M |
| Income taxes paid | SEK 0 | SEK 0 |
| Net cash from investing activities | -SEK 199.0K | -SEK 293.0K |
| Purchase of PP&E (capex) | SEK 199.0K | SEK 293.0K |
| Net cash from financing activities | SEK 21.4M | SEK 23.7M |
| Proceeds from borrowings | SEK 25.0M | SEK 24.5M |
| Lease liability payments | SEK 3.6M | SEK 3.6M |
| Balance sheet | ||
| Total assets | SEK 136.2M | SEK 177.1M |
| Non-current assets | SEK 56.7M | SEK 53.5M |
| Property, plant & equipment | SEK 9.8M | SEK 6.7M |
| Right-of-use assets | SEK 7.7M | SEK 3.8M |
| Current assets | SEK 79.6M | SEK 123.6M |
| Trade & other receivables | SEK 12.6M | SEK 12.3M |
| Cash & equivalents | SEK 66.9M | SEK 111.3M |
| Total equity | SEK 32.6M | SEK 115.8M |
| Non-current liabilities | SEK 3.5M | SEK 24.6M |
| Long-term borrowings | SEK 0 | SEK 24.5M |
| Lease liabilities (non-current) | SEK 3.5M | SEK 115.0K |
| Current liabilities | SEK 100.0M | SEK 36.7M |
| Lease liabilities (current) | SEK 3.4M | SEK 2.9M |
| Derived metrics | ||
| Free cash flow | -SEK 65.8M | -SEK 165.1M |
| Operating margin | -79.4% | -3183.6% |
| Net margin | -87.8% | -3132.1% |
| Return on equity | -254.7% | -153.6% |
| Cash conversion ratio | 0.79× | 0.93× |
| Capex coverage | -329.60× | -562.63× |
| Other reported items | ||
| Additional Paidin Capital | SEK 690.2M | SEK 690.2M |
| Adjusted Weighted Average Shares | 51.9M | 51.9M |
| Adjustments For Decrease Increase In Trade and Other Receivables | SEK 2.8M | SEK 3.6M |
| Adjustments For Increase Decrease In Trade and Other Payables | SEK 6.2M | SEK 5.0M |
| Adjustments To Reconcile Profit Loss Other Than Changes In Working Capital | SEK 4.6M | SEK 4.3M |
| Cash Flows From Used In Operations Before Changes In Working Capital | -SEK 74.6M | -SEK 173.5M |
| Current Accruals and Current Deferred Income Including Current Contract Liabilities | SEK 28.8M | SEK 14.9M |
| Current Borrowings and Current Portion of Noncurrent Borrowings | SEK 53.5M | SEK 0 |
| Current Prepayments and Current Accrued Income Including Current Contract Assets | SEK 6.3M | SEK 3.1M |
| Current Tax Assets Current | SEK 2.5M | SEK 518.0K |
| Depreciation Amortisation and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | SEK 4.6M | SEK 4.3M |
| Equity and Liabilities | SEK 136.2M | SEK 177.1M |
| Finance Income | SEK 2.5M | SEK 3.1M |
| Increase Decrease In Cash and Cash Equivalents | -SEK 44.4M | -SEK 141.5M |
| Intangible Assets Other Than Goodwill | SEK 46.9M | SEK 46.9M |
| Interest Paid Classified As Operating Activities | SEK 6.5M | SEK 199.0K |
| Interest Received Classified As Operating Activities | SEK 2.5M | SEK 3.1M |
| Issue of Convertible Instruments | — | SEK 2.8M |
| Issued Capital | SEK 1.0M | SEK 1.0M |
| Miscellaneous Other Operating Expense | SEK 2.1M | SEK 676.0K |
| Number of Shares Issued | 51.9M | 51.9M |
| Other Comprehensive Income | SEK 0 | SEK 0 |
| Other Current Liabilities | SEK 4.4M | SEK 8.4M |
| Other Current Receivables | SEK 3.9M | SEK 8.6M |
| Other Expense By Nature | SEK 136.3M | SEK 128.4M |
| Other Property Plant and Equipment | SEK 2.1M | SEK 2.7M |
| Proceeds From Noncurrent Borrowings | SEK 0 | SEK 2.8M |
| Retained Earnings | -SEK 658.6M | -SEK 575.5M |
| Revenue and Operating Income | SEK 114.1M | SEK 5.7M |
| Trade and Other Current Payables To Trade Suppliers | SEK 9.9M | SEK 10.5M |
| Weighted Average Shares | 51.9M | 51.9M |
Every line item above is a fact tagged in IRLAB Therapeutics AB's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (SEK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.